Canada markets open in 1 hour 42 minutes

Clearside Biomedical, Inc. (CLSD)

NasdaqGM - NasdaqGM Real Time Price. Currency in USD
Add to watchlist
1.1700+0.0200 (+1.74%)
At close: 04:00PM EDT
1.1200 -0.05 (-4.27%)
After hours: 05:39PM EDT
Full screen
Trade prices are not sourced from all markets
Previous Close1.1500
Open1.1700
Bid1.1400 x 200
Ask1.2000 x 300
Day's Range1.1500 - 1.1800
52 Week Range0.6500 - 2.1200
Volume62,192
Avg. Volume176,072
Market Cap87.435M
Beta (5Y Monthly)2.44
PE Ratio (TTM)N/A
EPS (TTM)-0.5500
Earnings DateAug 12, 2024 - Aug 16, 2024
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est5.29
  • GlobeNewswire

    Clearside Biomedical Appoints Dr. Glenn Yiu to its Scientific Advisory Board

    ALPHARETTA, Ga., July 11, 2024 (GLOBE NEWSWIRE) -- Clearside Biomedical, Inc. (Nasdaq: CLSD), a biopharmaceutical company revolutionizing the delivery of therapies to the back of the eye through the suprachoroidal space (SCS®), announced today the appointment of Glenn C. Yiu, M.D., Ph.D., Professor of Ophthalmology at the University of California, Davis, to its Scientific Advisory Board (SAB), which is comprised of industry-leading retinal physicians who provide medical and scientific expertise

  • GlobeNewswire

    Clearside Biomedical to Host Virtual Key Opinion Leader Event on the Use and Versatility of Suprachoroidal Drug Delivery

    - Webinar to be held on Wednesday, July 24, 2024 at 8:00 am ET - - Retina Specialists to Provide Insights and Real-World Experience with Suprachoroidal Drug Delivery - - Target Profile for CLS-AX in Wet AMD Landscape and Potential Opportunities for Clearside Pipeline Expansion - ALPHARETTA, Ga., June 27, 2024 (GLOBE NEWSWIRE) -- Clearside Biomedical, Inc. (Nasdaq: CLSD), a biopharmaceutical company revolutionizing the delivery of therapies to the back of the eye through the suprachoroidal space

  • GlobeNewswire

    Clearside Biomedical’s Leadership in Suprachoroidal Delivery Featured in Multiple Presentations at the Clinical Trials at the Summit Meeting

    - Broad Use of Suprachoroidal Injection Platform Highlighted Across Retinal Indications - - Robust Safety Profile and Encouraging Efficacy Data Reported Utilizing SCS Microinjector® - ALPHARETTA, Ga., June 12, 2024 (GLOBE NEWSWIRE) -- Clearside Biomedical, Inc. (Nasdaq: CLSD), a biopharmaceutical company revolutionizing the delivery of therapies to the back of the eye through the suprachoroidal space (SCS®), announced today that multiple oral presentations were delivered at the Clinical Trials a